<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We evaluated the effect of alefacept (Amevive), a novel dimeric fusion protein, in steroid resistant/dependent <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host-disease</z:e> (aGVHD) </plain></SENT>
<SENT sid="1" pm="."><plain>Seven patients were treated in eight aGVHD episodes </plain></SENT>
<SENT sid="2" pm="."><plain>GVHD grade at treatment initiation and at peak ranged 2-4 (median 2.5) and 2-4 (median 4), respectively </plain></SENT>
<SENT sid="3" pm="."><plain>System involvement at GVHD peak included skin (n=7), gastrointestinal tract (n=5) and liver (n=3) </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients responded </plain></SENT>
<SENT sid="5" pm="."><plain>However, one patient with skin GVHD and two with gastrointestinal GVHD featuring an early initial response (IR) exacerbated and CR was not achieved </plain></SENT>
<SENT sid="6" pm="."><plain>Skin GVHD responded rapidly with a median of 1 day to IR and 7 days to CR </plain></SENT>
<SENT sid="7" pm="."><plain>Intestinal response was slower with median 7.5 days to IR </plain></SENT>
<SENT sid="8" pm="."><plain>Of the four patients that achieved IR, CR was achieved in only one (40 days to CR) </plain></SENT>
<SENT sid="9" pm="."><plain>None of the patients had significant hepatic GVHD before treatment so no hepatic effect of alefacept could be determined </plain></SENT>
<SENT sid="10" pm="."><plain>No immediate alefacept-related side effects were observed </plain></SENT>
<SENT sid="11" pm="."><plain>Late side effects included <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> (aspergillus <z:hpo ids='HP_0000246'>sinusitis</z:hpo>, <z:hpo ids='HP_0002090'>pneumonia</z:hpo>, <z:e sem="disease" ids="C0004610" disease_type="Disease or Syndrome" abbrv="">bacteremia</z:e>, <z:e sem="disease" ids="C0343861" disease_type="Disease or Syndrome" abbrv="">pharyngeal thrush</z:e>), <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> and <z:e sem="disease" ids="C0085692" disease_type="Disease or Syndrome" abbrv="">hemorrhagic cystitis</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Three patients had CMV reactivation while on alefacept </plain></SENT>
<SENT sid="13" pm="."><plain>We conclude that alefacept may have a beneficial effect in controlling aGVHD </plain></SENT>
<SENT sid="14" pm="."><plain>Further investigations in larger cohorts of patients and controlled studies are warranted </plain></SENT>
</text></document>